Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Voyager and Novartis Collaborate on Advancing Gene Therapies for Huntington’s Disease and SMA

NextEdge Admin

04 Dec 2023

1 min 42 sec

Voyager Therapeutics has entered a strategic collaboration with Novartis to advance gene therapies for Huntington’s disease and spinal muscular atrophy (SMA). Novartis gains a target-exclusive license to utilize Voyager’s adeno-associated virus (AAV) capsids, developed through the TRACER platform, for the two specified diseases. Novartis will lead the development and commercialization of an SMA candidate, while Voyager will oversee preclinical work on a Huntington’s disease candidate, with Novartis taking over during clinical development and commercialization.

Voyager is set to receive $100 million upfront, including $20 million in newly issued equity, and is eligible for up to $1.2 billion in milestone payments based on preclinical, development, regulatory, and sales achievements. Additionally, Voyager will receive tiered royalties tied to global net sales of products utilizing its TRACER capsids. The upfront payment is expected to enhance Voyager’s financial position, extending its runway until mid-2026, according to CEO Alfred Sandrock. The collaboration leverages Novartis’ gene therapy expertise and Voyager’s innovative TRACER capsids, representing a significant step towards developing novel therapies for these debilitating conditions.